By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...

The trial is designed to assess the tolerability, efficacy, and safety of two different dosages of the therapy.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to ...

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to ...

An audio webcast will be accessible through the Investors section of the Company's website at www.anavex.com. A replay of the session will be available later that day. About Anavex Life Sciences Corp.

Oculis’ peptidomimetic small molecule has been shown to help protect the eyes of patients with inflammation of the optic ...

HONG KONG SAR - Media OutReach Newswire - 22 December 2024 - On December 20th, Fushi Technology is set to launch its AI Agent ...

LBT-3627 is under development for the treatment of Parkinson's disease. The drug candidate is administered through oral route. It is developed based on hybridtide scaffold technology. It acts by ...

Nano-formulation is the production of a drug or combination of drugs that use nanotechnology to enhance its therapeutic ...

Scientists from the Institute of Nano Science and Technology (INST) Mohali, an autonomous institute of the Department of ...